BIOTIE THERAPIES LTD has a total of 16 patent applications. Its first patent ever was published in 1995. It filed its patents most often in United States, Australia and Canada. Its main competitors in its focus markets biotechnology and pharmaceuticals are CHENGDU KANGHONG BIOTECHNOLOGIES CO LTD, HOLMS RUPERT DONALD and CB THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 3 | |
#2 | Australia | 2 | |
#3 | Canada | 2 | |
#4 | Hungary | 2 | |
#5 | Norway | 2 | |
#6 | Brazil | 1 | |
#7 | China | 1 | |
#8 | EPO (European Patent Office) | 1 | |
#9 | Poland | 1 | |
#10 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Microorganisms | |
#4 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Heino Jyrki | 6 |
#2 | Ivaska Johanna | 6 |
#3 | Smith David John | 5 |
#4 | Salmi Marko | 5 |
#5 | Bono Petri | 5 |
#6 | Jalkanen Sirpa | 5 |
#7 | Kapyla Jarmo | 3 |
#8 | Jalkanen Markku | 2 |
#9 | Kopylo Jarmo | 2 |
#10 | Kaepylae Jarmo | 1 |
Publication | Filing date | Title |
---|---|---|
HU0002234A3 | Vascular adhesion protein-1 having oxidase activity | |
US6096707A | Integrin binding peptide and use thereof | |
US6017727A | Syndecan enhancer element and syndecan stimulation of cellular differentiation | |
US5851993A | Suppression of tumor cell growth by syndecan-1 ectodomain |